High Vitamin D Levels May Downregulate Inflammation in Patients with Behçet’s Disease
Table 1
Demographics and clinical characteristics of BD patients and healthy controls.
Variables
BD patients
Controls
value
Age (years)
37.5
37.4
0.924
Median (Q1–Q3)
(24.3–51.2)
(24.1–51.4)
Female,(%)
14 (73.68)
70 (73.68)
N/A
Serum 25(OH)D levels (median) (nmol/L)
45.0
22.0
0.001
IQR (Q1–Q3)
(33.0–65.0)
(15.0–31.0)
25(OH)D deficiency (<20 nmol/L),(%)
0 (0)
42 (44.2)
25(OH)D insufficiency (20–40 nmol/L),(%)
6 (31.6)
36 (37.9)
On prednisolone,(%)
8 (42.1)
Nil
N/A
<7.5 mg daily,(%)
8 (42.1)
≥7.5 mg daily,(%)
0 (0)
DMARDs, (%)
15 (78.9)
Nil
N/A
On conventional DMARD,(%)
0 (0)
On anti-TNF therapy,(%)
15 (78.9)
Values are median and IQR, or numbers () and percentage (%) for counts. 25(OH)D: 25-hydroxyvitamin D; N/A: not applicable; IQR: interquartile range; Q1: 25th quartile; Q3: 75th quartile.
